CN112401245A - 一种鼠李糖乳杆菌微胶囊的制备方法 - Google Patents
一种鼠李糖乳杆菌微胶囊的制备方法 Download PDFInfo
- Publication number
- CN112401245A CN112401245A CN202011377020.2A CN202011377020A CN112401245A CN 112401245 A CN112401245 A CN 112401245A CN 202011377020 A CN202011377020 A CN 202011377020A CN 112401245 A CN112401245 A CN 112401245A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus rhamnosus
- probiotics
- layer
- double
- calcium alginate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000218588 Lactobacillus rhamnosus Species 0.000 title claims abstract description 56
- 239000003094 microcapsule Substances 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 235000010410 calcium alginate Nutrition 0.000 claims abstract description 18
- 239000000648 calcium alginate Substances 0.000 claims abstract description 18
- 229960002681 calcium alginate Drugs 0.000 claims abstract description 18
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical group [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims abstract description 18
- 229920001661 Chitosan Polymers 0.000 claims abstract description 13
- 239000002086 nanomaterial Substances 0.000 claims abstract description 13
- 239000002775 capsule Substances 0.000 claims abstract description 11
- 239000000463 material Substances 0.000 claims abstract description 11
- 239000011248 coating agent Substances 0.000 claims abstract description 8
- 238000000576 coating method Methods 0.000 claims abstract description 8
- 239000011162 core material Substances 0.000 claims abstract description 5
- 239000006041 probiotic Substances 0.000 claims description 45
- 235000018291 probiotics Nutrition 0.000 claims description 45
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims description 31
- 239000004005 microsphere Substances 0.000 claims description 17
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 11
- 235000013406 prebiotics Nutrition 0.000 claims description 11
- 235000010413 sodium alginate Nutrition 0.000 claims description 11
- 239000000661 sodium alginate Substances 0.000 claims description 11
- 229940005550 sodium alginate Drugs 0.000 claims description 11
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 9
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 8
- 229920001202 Inulin Polymers 0.000 claims description 7
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 7
- 229940029339 inulin Drugs 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 235000020183 skimmed milk Nutrition 0.000 claims description 5
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 4
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 4
- 238000005342 ion exchange Methods 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 2
- 230000009881 electrostatic interaction Effects 0.000 claims description 2
- 239000002861 polymer material Substances 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 230000002349 favourable effect Effects 0.000 claims 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 238000012258 culturing Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000001963 growth medium Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 7
- 238000009630 liquid culture Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 210000004211 gastric acid Anatomy 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 5
- 239000002105 nanoparticle Substances 0.000 description 5
- 230000000529 probiotic effect Effects 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 4
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 4
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000003833 bile salt Substances 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000635 electron micrograph Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000002122 magnetic nanoparticle Substances 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 2
- 239000001393 triammonium citrate Substances 0.000 description 2
- 235000011046 triammonium citrate Nutrition 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/10—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a carbohydrate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种鼠李糖乳杆菌微胶囊的制备方法。本发明涉及:双层包埋技术,其中芯材为吞食了磁性纳米材料的鼠李糖乳杆菌。囊材为双层结构,内层为海藻酸钙,外层为壳聚糖涂层。
Description
技术领域
本发明属于材料科学领域,具体是在芯材外部包裹囊材对其进行保护,芯材中益生菌通过吞食磁性纳米材料Fe3O4使益生菌在肠道内定植。
背景技术
当今社会,随着经济发展水平的提高,人们的生活质量也随之提高,然而一些常见的疾病如高血压、糖尿病、肾病等的发病率却在逐年提高,疾病显然成为了影响人类身体健康的杀手。
很多疾病的发生与发展都与肠道菌群息息相关。肠道微生物在人类的健康中扮演着重要的角色,益生菌是肠道微生物中的重要组成部分,影响宿主的营养、代谢、生理和免疫功能。益生菌主要通过自身的代谢产物改善机体的微生态环境,从而对人体发挥益生作用。为了满足市场需求,新型益生菌制品不断上市,益生菌制品发展非常迅速。将功能特性不同的益生菌经过复配,制备出益生菌微生态制剂,其有改善人体肠道菌群之效,拥有良好的开发潜力和市场前景。
常见的补充益生菌的方式往往会使益生菌穿肠而过,还未待其发挥作用便已被人体代谢掉。为解决这一问题,本发明诱导益生菌吞食磁性纳米材料,通过外加定向磁场借助纳米材料的磁性作用来达到定植的目的。通过添加益生元促进鼠李糖乳杆菌在肠道内增殖。同时,益生元作为冻干保护剂,保护菌体在冻干过程中的损伤。本研究中使用到的冻干保护剂包括菊粉、低聚果糖、脱脂牛奶。菊粉是一种天然的水溶性膳食纤维,几乎不能被胃酸水解和消化,只能在结肠被益生菌分解利用。菊粉和低聚果糖可以产生短链脂肪酸调节肠道pH,抑制腐生菌的生长,从而改善肠道环境。脱脂奶粉在鼠李糖乳杆菌冻干的过程中起保护作用,减轻冷冻干燥或复水对细胞的损害。尽可能保持原有的各种生理生化特性和生物学活性,这不仅能提高冻干过程中细菌的存活率,还能有效提高保藏期间的稳定性。
要想使益生菌发挥作用,首先要保证其能够顺利通过人体的胃酸环境,到达肠道定植下来,然而人体胃液中的酸性环境和肠道中的胆汁盐溶液会对益生菌产生极大的伤害。益生菌对酸性环境的抗逆性差,使得益生菌经口服后存活率低,很难达到最低有效浓度107cfu/mL。口服给药会导致大多数益生菌活力受到损失,益生菌活力的降低会导致其益生效果降低,因而限制了益生菌的使用,降低了其对人体的保健作用。
双包埋技术包裹益生菌是一种新兴的方法,可以有效地解决益生菌在通过胃肠道时胃酸和胆盐等,对其造成损伤这一问题。双包埋技术通过选择合适的壁材将益生菌包裹起来,减少益生菌与外界环境的接触,提高了益生菌对酸性环境的耐受性,增加了益生菌的存活率。从而促进益生菌发挥对人体的保健作用。
双层包埋技术中囊材内层是由天然高分子材料海藻酸盐与钙离子经过离子交换形成的具有良好碳骨架的微胶囊,囊材外层是壳聚糖涂层。海藻酸钠易溶于水,遇Ca2+(或其它二价阳离子结合)形成凝胶的条件温和,凝胶性能不受温度影响。海藻酸盐具有酸凝胶特性,在酸性条件下(胃酸中)呈凝胶状态,中性条件下(肠道中)溶解靶向释放。通过在酸中形成更加紧密的凝胶结构防止胃酸对益生菌的腐蚀,由于其在中性条件下溶解,可以有效地控制益生菌的靶向释放。安全无毒,适合于益生菌的包封。双层包埋技术对于益生菌的保护具有积极的作用。并能使益生菌在肠道内可控性释放。
发明内容
本发明涉及一种双层包埋鼠李糖乳杆菌微胶囊的制备。本发明使益生菌吞食磁性纳米材料获得磁性,有利于口服靶向肠道定植。通过双层包埋技术减少益生菌在经过胃肠道时,胃酸、胆盐对益生菌产生的危害。
本发明提供双层结构胶囊的制备方法,将海藻酸钠溶液、益生元及益生菌混合。使用注射器将上述混合液滴入氯化钙溶液中,混合液中海藻酸钠与氯化钙溶液进行离子交换形成微球。外层壳聚糖通过静电结合包裹在海藻酸钙微球表面形成囊材外层,最终获得双层结构微囊。
具体可以分为以下几个步骤:
(1)鼠李糖乳杆菌的培养
将冻存的鼠李糖乳杆菌涂布于MRS固体培养基中,纯化三代后挑取单菌落接种于液体培养基中。
(2)诱导鼠李糖乳杆菌吞食磁性纳米材料
将鼠李糖乳杆菌与磁性纳米材料共培养五代,从而诱导其吞食磁性纳米材料。
(3)鼠李糖乳杆菌吞食磁性纳米材料的定性定量检测
定性检测:透射电镜观察
定量检测:邻菲罗啉比色法
(4)双层包裹形成同心圆微球
将海藻酸钠溶液、益生元与鼠李糖乳杆菌混合,通过挤压法滴入氯化钙溶液中获得海藻酸钙微球。将海藻酸钙微球转移至壳聚糖溶液中,二者通过静电作用结合最终获得双包埋微球。
附图说明
图1:Fe3O4的电镜图。
图2:鼠李糖乳杆菌吞食Fe3O4的电镜图。
图3:Fe3O4的红外光谱。
图4:Fe3O4的X-射线衍射图谱。
粒度分析仪测得的Fe3O4粒径图谱。
图5-1:Fe3O4纳米粒子通过光强度分布表征的粒径图谱。
图5-2:Fe3O4纳米粒子通过数量分布表征的粒径图谱。
图6:海藻酸钙包裹鼠李糖乳杆菌的电镜图。
具体实施方式
鼠李糖乳杆菌的培养:将鼠李糖乳杆菌甘油菌涂布于MRS固体培养基中,纯化三代后挑取单菌落接种于液体培养基中。
优选的,MRS固体培养基的成分为:蛋白胨、牛肉浸粉、酵母浸粉、葡萄糖、磷酸氢二钾、柠檬酸三铵、乙酸钠、硫酸镁、硫酸锰、吐温-80、琼脂;
优选的,MRS液体培养基的成分为:蛋白胨、牛肉浸粉、酵母浸粉、葡萄糖、磷酸氢二钾、柠檬酸三铵、乙酸钠、硫酸镁、硫酸锰、吐温-80;
优选的,鼠李糖乳杆菌的培养条件为:在37℃固体培养基中,培养36-48h;在37℃液体培养基中,培养12-16h;
优选的,鼠李糖乳杆菌需培养纯化三次后接种于MRS液体培养基中;
Fe3O4的制备:FeCl3·6H2O与FeCl2·4H2O混合,在N2保护下高速电动搅拌加入NaOH,水浴恒温维持一段时间后,获得Fe3O4纳米粒子(见图1)。
优选的,FeCl3·6H2O的浓度为:2M;
优选的,FeCl3·6H2O的体积为:15mL;
优选的,FeCl2·4H2O的浓度为:1M;
优选的,FeCl2·4H2O的体积为:15mL;
优选的,NaOH的浓度为:4M;
优选的,NaOH的体积为:31mL;
优选的,水浴恒温时间为:30-40min;
优选的,水浴恒温温度为:60℃;
优选的,整个体系在pH稳定在10-11之间;
优选的,应保持匀速缓慢地滴加NaOH;
Fe3O4的结构与形态分析:用红外光谱证明,产物为Fe3O4(见图3)。
优选的,测定红外的波长为:400-4000cm-1;
优选的,Fe3O4:KBr应为:1∶150;
用X-射线衍射证明,产物为Fe3O4(见图4)。
优选的,工作电压为:30-50kV;
优选的,工作电流为:20-40mA;
优选的,扫描速度为:5°/min;
Fe3O4的粒径分析:取1mL产物至样品池中,测量(见图5-1、图5-2)。
优选的,Fe3O4浓度应稀释为:1mg/mL;
鼠李糖乳杆菌生长曲线的测定:取鼠李糖乳杆菌,接种于新鲜的液体培养基中,取样并测定其OD600,记录数据。
优选的,鼠李糖乳杆菌的接种量为:1%;
优选的,应选择培养12-16h后的鼠李糖乳杆菌进行接种;
优选的,取样时间间隔为:每隔一个小时取一次样;
鼠李糖乳杆菌和Fe3O4共培养:取鼠李糖乳杆菌菌悬液,接种于新鲜的液体培养基中,同时加入Fe3O4与鼠李糖乳杆菌于培养箱中共培养。
优选的,与鼠李糖乳杆菌共培养的Fe3O4的浓度为:50-100μg/mL;
优选的,鼠李糖乳杆菌与Fe3O4共培养一代的时间为:12-16h;
优选的,鼠李糖乳杆菌与Fe3O4共培养的温度为:37℃;
定性测定:将与Fe3O4共培养的鼠李糖乳杆菌滴在碳包裹的铜网格上,室温下干燥后用透射电镜观察(见图2)。
定量测定:将与Fe3O4共培养的鼠李糖乳杆菌,水洗,收集菌体。加入HCl使Fe3O4溶解为Fe2+、Fe3+,NaOH调节反应体系pH。Fe3+由盐酸羟胺还原至Fe2+,加入邻菲罗啉显色,醋酸钠缓冲液作为缓冲体系,测定其吸光度。
优选的,鼠李糖乳杆菌与Fe3O4共培养至5-10代;
优选的,鼠李糖乳杆菌水洗的次数为:3-8次;
优选的,收集鼠李糖乳杆菌菌体的转速为:1000-3000r/min;
优选的,使Fe3O4溶解的HCl的量为:1mL;
优选的,使Fe3O4溶解的HCl的浓度为:12M;
优选的,NaOH调节反应体系pH为:1-3;
优选的,还原Fe3+的盐酸羟胺的量为:1mL;
优选的,用来显色邻菲罗啉的量为:2mL;
优选的,作为缓冲体系的醋酸钠缓冲液加入的量为:5mL;
优选的,显色后测定吸光度的波长范围为:500-520nm;
双层包裹:本发明将益生元、鼠李糖乳杆菌与海藻酸钠混合,挤压至氯化钙溶液中获得海藻酸钙微球。取出海藻酸钙微球,水洗后转移至壳聚糖溶液混合,得到双层包裹的胶囊(见图6)。
优选的,益生元中脱脂牛奶的量为:10-30质量份;
优选的,益生元中低聚果糖的量为:1-5质量份;
优选的,益生元中菊粉的量为:1-5质量份;
优选的,鼠李糖乳杆菌的浓度为:107-109cfu/mL;
优选的,海藻酸钠的量为:0.5-3质量份;
优选的,氯化钙的量为:1-3质量份;
优选的,海藻酸钠与氯化钙离子交换的时间为:20-40min;
优选的,水洗次数为:3-5次;
优选的,壳聚糖的浓度为:1-3g/L;
优选的,海藻酸钙微球在壳聚糖溶液中混合的转速为:150-300r/min;
优选的,海藻酸钙微球在壳聚糖溶液中混合的时间为:10-30min;
实施例
通过实施例来更详细地说明本发明。本发明并不解释为限定于这些实施例。
实施例1:
(1)鼠李糖乳杆菌的培养:将鼠李糖乳杆菌甘油菌涂布于MRS固体培养基中,挑取单菌落于MRS固体培养基中,在37℃培养条件下培养36h,纯化三次。从第三次纯化的平板上挑取单菌落接种在MRS液体培养基中,培养12h。
(2)Fe3O4的制备:15mL 2M的FeCl3·6H2O与15mL 1M的FeCl2·4H2O混合,在N2保护、60℃恒温水浴下高速电动搅拌与31mL 4M的NaOH混合,剧烈搅拌30min后结束反应,获得Fe3O4纳米粒子。
(3)鼠李糖乳杆菌和Fe3O4的共培养:取培养12h后的菌悬液,以1%的接种量接种于新鲜的液体培养基中。同时加入100μg/mL的Fe3O4,与菌液于37℃培养箱中共培养,每隔12h传一代。
(4)将益生元:10质量份的脱脂牛奶、1质量份的低聚果糖、1质量份的菊粉和107-109cfu/mL鼠李糖乳杆菌,与0.5质量份的海藻酸钠混合,挤压至1%的氯化钙溶液中获得海藻酸钙微球。取出海藻酸钙微球,水洗5次后转移至2g/L壳聚糖溶液中,150r/min摇晃10min后取出微球。水洗5次得到直径为2.5μm的双层结构微胶囊。
实施例2:
除了将(2)中水浴温度改为30℃以外,其他过程与实施例1相同,制备了直径为2.5μm的包裹了鼠李糖乳杆菌的双层结构微胶囊。
实施例3:
除了将与鼠李糖乳杆菌共培养的Fe3O4的浓度(3)改为50μg/mL外,其他过程与实施例1相同,制备了直径为2.5μm的包裹了鼠李糖乳杆菌的双层结构微胶囊。
实施例4:
除了将(4)中海藻酸钠的浓度改为2.5%外,其他过程与实施例1相同,制备了直径为2.5μm的包裹了鼠李糖乳杆菌的双层结构微胶囊。
实施例5:
(1)鼠李糖乳杆菌生长曲线的测定:取培养12h后的鼠李糖乳杆菌,以1%的接种量接种于新鲜的液体培养基中。初始时间记为0时,从0时开始取样,每隔一个小时取一次样并测定其OD600,记录数据。
(2)定性测定:将与Fe3O4共培养的鼠李糖乳杆菌滴在碳包裹的铜网格上,室温下干燥后用透射电镜观察。
(3)定量测定:将与Fe3O4共培养5代的鼠李糖乳杆菌,水洗5次,收集菌体。加入1mL12M的HCl使Fe3O4溶解为Fe2+、Fe3+,NaOH调节反应体系至pH=2。Fe3+由盐酸羟胺还原至Fe2+,加入邻菲罗啉显色,510nm下测定其吸光度。
用粒度仪测量实施例1和实施例2中由不同水浴温度制备出的磁性纳米粒子的粒径。测量结果显示不同温度制备出的纳米粒子,粒径不受温度的影响。
测实施例1和实施例3与磁性纳米粒子共培养的鼠李糖乳杆菌的生长曲线,实施例1中鼠李糖乳杆菌的生长受到抑制,实施例3中鼠李糖乳杆菌的生长未受到影响。
实施例4与实施例1相比海藻酸钙微球弹性和硬度都较好。
实施例5中,通过测定鼠李糖乳杆菌的OD600测得其生长曲线,在4h时进入对数生长期,在12h时进入稳定期。
实施例5中,透射电镜结果显示,鼠李糖乳杆菌吞食了纳米材料Fe3O4。
实施例5中,定量结果显示,鼠李糖乳杆菌对Fe3O4的吞食率为53%。
Claims (6)
1.一种靶向肠道的双层包埋的鼠李糖乳杆菌微胶囊,其特征在于:由益生元及益生菌混合构成的芯材、由天然高分子材料海藻酸钠构成的囊材内层以及与内层通过静电作用结合的壳聚糖涂层构成的囊材外层,形成呈同心圆状的双层结构微胶囊。
2.根据权利要求1所述,益生元包括:菊粉、脱脂奶粉、低聚果糖。
3.根据权利要求1所述,益生菌是吞食了磁性纳米材料Fe3O4的鼠李糖乳杆菌。
4.根据权利要求3所述,磁性纳米材料Fe3O4的粒径在5-10nm之间,上述粒径有利于鼠李糖乳杆菌对Fe3O4的吞食。
5.根据权利要求1所述,海藻酸钠在室温下为液体状态,与氯化钙混合通过离子交换形成凝胶状的海藻酸钙微球。
6.根据权利要求1所述,囊材内层的海藻酸钙带负电荷,囊材外层的壳聚糖涂层带正电荷,二者通过静电作用在海藻酸钙表面结合形成双层微球结构。通过双层包埋技术包裹鼠李糖乳杆菌,保护该益生菌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011377020.2A CN112401245A (zh) | 2020-12-01 | 2020-12-01 | 一种鼠李糖乳杆菌微胶囊的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011377020.2A CN112401245A (zh) | 2020-12-01 | 2020-12-01 | 一种鼠李糖乳杆菌微胶囊的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112401245A true CN112401245A (zh) | 2021-02-26 |
Family
ID=74829027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011377020.2A Pending CN112401245A (zh) | 2020-12-01 | 2020-12-01 | 一种鼠李糖乳杆菌微胶囊的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112401245A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113925114A (zh) * | 2021-08-31 | 2022-01-14 | 蓝色麦田科技(北京)有限公司 | 一种肠胃调理、提高消化吸收的猫粮及其制备方法 |
-
2020
- 2020-12-01 CN CN202011377020.2A patent/CN112401245A/zh active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113925114A (zh) * | 2021-08-31 | 2022-01-14 | 蓝色麦田科技(北京)有限公司 | 一种肠胃调理、提高消化吸收的猫粮及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5183848B2 (ja) | 消化器系障害の予防または治療のための水素依存性酢酸生成株の使用 | |
Islam et al. | Microencapsulation of live probiotic bacteria | |
Chen et al. | Graphene oxide as an anaerobic membrane scaffold for the enhancement of B. adolescentis proliferation and antagonistic effects against pathogens E. coli and S. aureus | |
CN113925974B (zh) | 一种可靶向肠道肿瘤的抗癌复合物及其制备方法和应用 | |
CN111534435B (zh) | 一种可提高双歧杆菌耐酸性的冻干保护剂及其应用 | |
CN115039884A (zh) | 一种具有抑制奇异变形杆菌生长作用的鼠李糖乳杆菌及其益生菌组合物、发酵液和应用 | |
Wei et al. | Activation of a passive, mesoporous silica nanoparticle layer through attachment of bacterially-derived carbon-quantum-dots for protection and functional enhancement of probiotics | |
CN112890204A (zh) | 一种利用葡萄籽提取物作为益生元的微胶囊及其制备方法 | |
CN112401245A (zh) | 一种鼠李糖乳杆菌微胶囊的制备方法 | |
CN113893353B (zh) | 一种提高肠道益生菌在口服递送过程中存活率的方法 | |
Kim et al. | pH‐sustaining nanostructured hydroxyapatite/alginate composite hydrogel for gastric protection and intestinal release of Lactobacillus rhamnosus GG | |
CN109602722B (zh) | 一种酵母包被的益生菌微胶囊制剂、制备方法及其应用 | |
El-Sayed et al. | Facile green preparation of Cr2O3 nanoparticles combined with probiotics in hydro-beads to produce integrated yoghurt | |
WO2022266840A1 (zh) | 益生菌微胶囊及其制备方法和用途 | |
JP3520012B2 (ja) | 栄養素補完剤として、かつ、腸障害の治療および細菌フローラの改変に適した組成物 | |
CN113230284A (zh) | 一种基于多维交联的合生素微囊化制剂及其制备方法和应用 | |
Both et al. | Effect of microencapsulation on viability and survival in simulated gut conditions of probiotic bacteria | |
CN115737828A (zh) | 一种包含螺旋藻的复合物及其制备方法和应用 | |
WO2011122934A2 (en) | Bioencapsule and method thereof | |
Jiang et al. | 2D Nanozymes Modulate Gut Microbiota and T‐Cell Differentiation for Inflammatory Bowel Disease Management | |
CN113397170A (zh) | 一种用于调节人体肠道菌群的海洋益生元组合物及其应用 | |
Anagha et al. | Probiotic with gluten reduction property and its encapsulation in synbiotic aloe vera gel-alginate capsules with banana powder as prebiotic | |
CN114645004B (zh) | 一种保持功效递送的动物双歧杆菌乳亚种菌剂的制备方法 | |
Li et al. | Preparation of alginate-gelatin capsules and its properties | |
Hu et al. | Efficient biosynthesis of selenium nanoparticles using Lacticaseibacillus paracasei SCFF20: A potential bio-factory for selenite conversion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210226 |